Shanghai Zj Bio-Tech688317.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Shanghai Zj Bio-Tech (688317.SH) trades at a negative P/E (-50.21x, due to a recent net loss), P/B of 1.01x, P/S of 30.60x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 31st percentile over the trailing 10Y window (vs. 58th percentile over 3Y); P/S sits at the 80th percentile over the trailing 10Y window (vs. 63rd percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 6th percentile within its industry and the 9th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 7.94%, ranking at the 94th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Shanghai Zj Bio-Tech operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688317 · SSE: 688317 · 688317
Want the full picture on whether Shanghai Zj Bio-Tech (688317.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -50.21 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.01 | ||||||
| P/S (TTM) | 30.60 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 7.94% |